104 related articles for article (PubMed ID: 2266815)
1. Intensification of adjuvant chemotherapy in patients with primary breast cancer and positive axillary nodes.
Elias EG
Md Med J; 1990 Dec; 39(12):1072-3. PubMed ID: 2266815
[No Abstract] [Full Text] [Related]
2. Post-operative therapy of breast cancer: rationale for adjuvant chemotherapy.
Butler WM
J S C Med Assoc; 1984 Jan; 80(1):15-6. PubMed ID: 6371378
[No Abstract] [Full Text] [Related]
3. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant systemic therapy for breast cancer. Issues for primary care physicians.
Berkowitz LD; Love N
Postgrad Med; 1995 Oct; 98(4):85-8, 91, 94. PubMed ID: 7567725
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
6. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.
Kuerer HM; Newman LA; Buzdar AU; Dhingra K; Hunt KK; Buchholz TA; Binkley SM; Strom EA; Ames FC; Ross MI; Feig BW; McNeese MD; Hortobagyi GN; Singletary SE
Cancer J Sci Am; 1998; 4(4):230-6. PubMed ID: 9689981
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
8. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
9. [Adjuvant therapy for breast cancer patient with 10 or more involved nodes].
Enomoto K
Gan To Kagaku Ryoho; 1995 Apr; 22 Suppl 1():88-93. PubMed ID: 7747998
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant chemotherapy of axillary node-negative carcinoma of the breast using doxorubicin and cyclophosphamide.
Brooks RJ; Jones SE; Salmon SE; Chase EM; Davis SL; Moon TE; Giordano GF; Ketchel SJ; Jackson RA
NCI Monogr; 1986; (1):135-7. PubMed ID: 3534586
[TBL] [Abstract][Full Text] [Related]
12. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trials in breast cancer: a tabular summary. Part 1: Primary breast cancer.
Conrad B; Kieser R
Arch Geschwulstforsch; 1986; 56(3):211-36. PubMed ID: 3524501
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
15. [Adjuvant therapy of breast cancer. 1: Cytostatic therapy].
Possinger K; Sauer HJ; Wilmanns W
Fortschr Med; 1986 Aug; 104(29):552-5. PubMed ID: 3758881
[No Abstract] [Full Text] [Related]
16. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
Botti C; Vici P; Lopez M; Scinto AF; Cognetti F; Cavaliere R
J Am Coll Surg; 1995 Sep; 181(3):202-8. PubMed ID: 7670678
[TBL] [Abstract][Full Text] [Related]
18. When is adjuvant treatment of stage IIIA breast cancer recommended?
Siemers R
Oncology (Williston Park); 1987 Dec; 1(10):39. PubMed ID: 3275339
[No Abstract] [Full Text] [Related]
19. [Reduced-dose adjuvant CMF-chemotherapy combined with postoperative irradiation in breast cancer with lymphatic metastases. A prospective study of 45 patients].
Sauerwein W; Nitz U; Rehwald U; Lapukins Z; Schmitt G; Scherer E
Strahlentherapie; 1985 Jun; 161(6):354-61. PubMed ID: 3839325
[TBL] [Abstract][Full Text] [Related]
20. [Adjuvant therapy of breast cancer].
Semiglazov VF; Abzumanov AS; Bozhok AA; Ivanov VG; Ivanova OA; Barash NIu; Topuzov EE; Seleznev IK; Migmanova NSh; Popova RT; Nurgaziev KSh
Khirurgiia (Mosk); 2001; (5):52-60. PubMed ID: 11505673
[No Abstract] [Full Text] [Related]
[Next] [New Search]